Trump nominates Marty Makary, who opposed COVID ...
President-elect Donald Trump has nominated a critic of COVID-19 health measures to lead the Food and Drug Administration.
www.cbsnews.comHere’s a concise update on Marty Makary based on recent reporting.
-
Nomination and confirmation context: In late 2024, President Trump announced Makary as a nominee to lead the FDA, with confirmation proceedings occurring in early 2025. This positioned him as a prominent critic of certain COVID-19 public-health measures entering a top regulatory role. Makary’s candidacy drew coverage highlighting his background as a surgeon and health-policy commentator who had questioned some pandemic strategies. He was confirmed by the Senate and began serving as FDA commissioner in 2025.[1][2][3][5]
-
Public stance and coverage during tenure: Coverage during hearings and early tenure framed Makary as someone who would push for regulatory modernization and new approaches at the FDA, including discussions about transparency, trial processes, and the agency’s oversight of medical products. Commentaries and profiles noted a track record of criticizing the medical establishment and advocating for reforms, which influenced how observers assessed his potential leadership style and policy priorities at the FDA.[3][5]
-
Notable developments in 2026: There were reports and conversations around political and industry pressures affecting his role, including speculation about ongoing debates over FDA rulings and the broader direction of U.S. health policy. Some articles referenced Marcus Makary’s emergence as a definer of the agency’s direction amid shifting political dynamics.[2][3]
If you’d like, I can pull the latest article links and summarize fresh developments in the last week or month, or focus on a specific aspect (FDA reforms, pandemic-related policies, or Makary’s public statements). Please tell me which you prefer.